Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $10.20 and traded as high as $11.56. Oramed Pharmaceuticals shares last traded at $10.93, with a volume of 421,229 shares trading hands.
Several analysts have recently weighed in on ORMP shares. Canaccord Genuity started coverage on shares of Oramed Pharmaceuticals in a research note on Monday, April 26th. They issued a “buy” rating and a $27.00 price objective for the company. Alliance Global Partners lifted their price objective on shares of Oramed Pharmaceuticals from $11.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, April 27th. Aegis reiterated a “buy” rating on shares of Oramed Pharmaceuticals in a research note on Monday, February 15th. Finally, National Securities initiated coverage on shares of Oramed Pharmaceuticals in a research note on Tuesday, February 9th. They issued a “buy” rating for the company. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $20.25.
The firm’s 50-day moving average is $10.21 and its 200-day moving average is $7.46. The firm has a market cap of $333.11 million, a price-to-earnings ratio of -17.77 and a beta of 1.90.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Monday, April 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Oramed Pharmaceuticals had a negative net margin of 572.31% and a negative return on equity of 42.75%. As a group, sell-side analysts expect that Oramed Pharmaceuticals Inc. will post -0.77 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of ORMP. Oppenheimer & Co. Inc. purchased a new position in Oramed Pharmaceuticals during the 4th quarter worth $51,000. Dorsey Wright & Associates purchased a new position in Oramed Pharmaceuticals during the 1st quarter worth $52,000. HighTower Advisors LLC purchased a new position in Oramed Pharmaceuticals during the 4th quarter worth $57,000. LPL Financial LLC purchased a new position in Oramed Pharmaceuticals during the 4th quarter worth $60,000. Finally, Endurance Wealth Management Inc. boosted its holdings in Oramed Pharmaceuticals by 500.0% during the 1st quarter. Endurance Wealth Management Inc. now owns 6,000 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 5,000 shares during the last quarter. 2.93% of the stock is currently owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Read More: What are some reasons analysts would give stocks a buy rating?